IOVANCE BIOTHERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $311.75 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-05-10
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $311.75M, a 2106.16% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $14.13M, a 78.32% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $65.18M, a 68.67% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $38.65M.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $153.85M, a 1242.60% increase from fiscal 2021.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $11.46M, a 78.56% decline from fiscal 2020.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $53.44M.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was -$62.73M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-03-31 | $311.75M 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $153.85M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $40.48M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $30.19M 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $14.13M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $11.46M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | -$8.18M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $15.99M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $65.18M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $53.44M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $54.42M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $146.72M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $38.65M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$62.73M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$37.81M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $210.00K 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$28.06M 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | -$63.22M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$64.64M 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | $100.64M 10-Q · filed 2019-08-01 | |||
| 2017-12-31 | $38.66M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |